DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Ribas A et al.
BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
J Clin Oncol 2011; 29 (suppl; abstr 8509)
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.